Monopar Therapeutics Inc. found using ticker (MNPR) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 40 and 11 with the average target price sitting at 30.33. Now with the previous closing price of 5.64 this is indicating there is a potential upside of 437.8%. The 50 day MA is 5.06 while the 200 day moving average is 6.05. The company has a market capitalisation of $69m. Find out more information at: http://www.monopartx.com
Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo EspaÃ±ol de InvestigaciÃ³n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.